Literature DB >> 27408468

Extranodal Marginal Zone Lymphoma of the Parotid Gland.

Sedat Aydın1, Mehmet Gökhan Demir1, Nagehan Özdemir Barışık2.   

Abstract

Non Hodgkin lymphomas correspond to 25 % of all head and neck cancers. These rare tumors only include less than 5 % of malign tumors in parotid region. Differential diagnosis of these tumors cover many malign and benign tumors of the parotid gland. Definite diagnosis depends on sufficient tissue material of parotidectomy specimen. Treatment modality is surgical removal of the lesion with or without additional radiation and chemotherapy depending on the stage of the tumor. Prognosis is better than other forms of the B-cell lymphoma. We present a 54 year old woman who suffered from progressively and slowly growing mass on parotid region, without any inflammatory disease or chronic infection, diagnosed with mucosa associated lymphoid tissue lymphoma of the parotid gland. Parotid gland was totally excised by superficial parotidectomy and there is no recurrence after 5 years postoperative period.

Entities:  

Keywords:  Lymphoid neoplasm; Marginal zone lymphoma; Mucosa associated lymphoid tissue lymphoma; Parotid gland

Year:  2016        PMID: 27408468      PMCID: PMC4925607          DOI: 10.1007/s12663-016-0882-x

Source DB:  PubMed          Journal:  J Maxillofac Oral Surg        ISSN: 0972-8270


  16 in total

1.  Parotid MALT lymphoma in HIV infected children.

Authors:  P Corr; M Vaithilingum; R Thejpal; P Jeena
Journal:  J Ultrasound Med       Date:  1997-09       Impact factor: 2.153

Review 2.  Lymphoma of the thyroid and head and neck.

Authors:  M J Beasley
Journal:  Clin Oncol (R Coll Radiol)       Date:  2012-04-02       Impact factor: 4.126

3.  Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial.

Authors:  Lisa Lowry; Paul Smith; Wendi Qian; Stephen Falk; Kim Benstead; Tim Illidge; David Linch; Martin Robinson; Andrew Jack; Peter Hoskin
Journal:  Radiother Oncol       Date:  2011-06-12       Impact factor: 6.280

4.  Development of malignant lymphoma in myoepithelial sialadenitis (Sjögren's syndrome).

Authors:  U Schmid; D Helbron; K Lennert
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1982

5.  Mucosa-associated lymphoid tissue lymphoma of the salivary glands: MR imaging findings including diffusion-weighted imaging.

Authors:  Hiroki Kato; Masayuki Kanematsu; Hiroo Goto; Keisuke Mizuta; Mitsuhiro Aoki; Bunya Kuze; Yoshinobu Hirose
Journal:  Eur J Radiol       Date:  2012-01-31       Impact factor: 3.528

6.  MALT lymphoma presenting as a cystic salivary gland mass.

Authors:  D B Rosenstiel; W R Carroll; C M Listinsky
Journal:  Head Neck       Date:  2001-03       Impact factor: 3.147

7.  Primary salivary gland lymphoma: a clinicopathologic study of 23 cases in Taiwan.

Authors:  Po Dunn; Tseng-tong Kuo; Lee-Yung Shih; Tung-Liang Lin; Po-Nan Wang; Ming-Chung Kuo; Chung-Chih Tang
Journal:  Acta Haematol       Date:  2004       Impact factor: 2.195

8.  Lymphomas of salivary glands.

Authors:  M J Gleeson; M H Bennett; R A Cawson
Journal:  Cancer       Date:  1986-08-01       Impact factor: 6.860

9.  18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma.

Authors:  Martha Hoffmann; Kurt Kletter; Alexander Becherer; Ulrich Jäger; Andreas Chott; Markus Raderer
Journal:  Oncology       Date:  2003       Impact factor: 2.935

10.  Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma.

Authors:  Chava Perry; Yair Herishanu; Ur Metzer; Osnat Bairey; Rosa Ruchlemer; Leonor Trejo; Elizabeth Naparstek; Einat Even Sapir; Aaron Polliack
Journal:  Eur J Haematol       Date:  2007-07-27       Impact factor: 2.997

View more
  1 in total

1.  Mucosa-associated lymphoid tissue lymphoma of the accessory parotid gland presenting as a simple cheek mass: A case report.

Authors:  Jae Ha Hwang; Dong Wan Kim; Kwang Seog Kim; Sam Yong Lee
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.